RMD at a glance
ResMed (RMD, SEC CIK 943819) filed its latest 10-K annual report on August 13, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), ResMed (RMD) reported revenue of $5.7 billion (up 9.9% from FY2025) and net income of $1.5 billion. Diluted EPS was $10.43.
- As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding ResMed (RMD) shares worth $11.6 billion in 13F-HR filings.
- In the last 90 days, RMD insiders reported 0 open-market purchases ($0) and 6 open-market sales ($3.8M) on Form 4, a net sale of $3.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $5.7B
- +9.9% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$3.8M
- 13F holders
- 41 funds
- $11.6B · +1 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.02 · Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $5,653M, up 10% YoY ($507M increase); Sleep and Breathing Health +10%, Residential Care Software +5%
- Gross margin 61.1% vs 59.4%, operating margin 33.4% vs 32.7%; non-GAAP operating margin 36.1% vs 34.3%
- Best segment: Sleep and Breathing Health revenue $4,978M (+10%); worst: Residential Care Software $676M (+5%)
- Operating cash flow $1.8B; treasury stock repurchases $700M; dividends $350M paid; capex and acquisitions total $545M investing cash outflow
- Management outlook implies continued growth and strategic acquisitions; risks include foreign currency effects, global minimum tax, and regulatory environment
Risk Factors
- Direct Medicare oversight risk due to acquisitions of VirtuOx and Noctrix, subject to Anti-Kickback Statute, Stark Law, False Claims Acts, and HIPAA compliance
- Geopolitical risk from Uyghur Forced Labor Prevention Act (effective June 2022) and Russia-Ukraine conflict potentially disrupting suppliers of raw materials
- Supply chain risk from reliance on single-source suppliers and Chinese export controls on rare earth magnets, impacting cost and availability of components
- Competitive risk from Philips' product recall and re-entry, plus pharmaceuticals like GLP-1 affecting market for OSA treatment devices
- Financial risk from $660 million debt (June 30, 2026) increasing vulnerability to adverse conditions and limiting financial flexibility
Business Overview
- Core business model: Global leader in AI-powered digital health and cloud-connected medical devices for sleep and breathing health, plus residential care software
- New acquisition: Noctrix Health in June 2026, expanding portfolio into restless legs syndrome treatment with FDA De Novo classified wearable device
- Strategic shift: Sold MatrixCare business for $490 million to focus on core sleep, breathing, and connected home-based healthcare growth areas
- Employee count steady at approximately 11,370 with 31% in Americas, 31% Asia, 15% Australia, 23% Europe; 13% global turnover rate in FY 2026
- Noteworthy development: Launched Smart Comfort feature in myAir app in early 2026, first FDA-cleared AI-enabled medical device recommending personalized therapy comfort settings
AI summary of the RMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to the fiscal 2026 Form 10-K risk factors as of September 30, 2026
- Carried-forward risks include regulatory compliance, product quality, cybersecurity, competition, and market demand
- Financial exposures remain those identified in the fiscal 2026 Form 10-K, including liquidity, debt, currency, and customer concentration risks
Management Discussion & Analysis
- Revenue $1,415M, up $79M or 6% YoY
- Gross margin 61.5% vs 61.2% YoY; net income $418M vs $349M
- Best segment: Sleep and Breathing Health $1,260M, up 8%; worst: Residential Care Software $155M, down 7%
- Cash $1.0B vs $1.5B at June 30; operating cash flow $422M vs $457M
- $936M share repurchases and $250M debt repayment; inflationary component costs expected through fiscal 2027
AI summary of the RMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ronald Taylor retired from the Board at the November 18, 2026 annual meeting, reducing director count from 11 to 10
- FY2027 executive PSUs shift to three-year Adjusted EPS and Adjusted Revenue goals, replacing recent absolute and relative TSR-based design
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected all ten director nominees to serve through the 2027 annual meeting
- PwC ratified as independent auditor for fiscal year ending June 30, 2027, with 109,994,316 votes supporting
Item 8.01: Other Events
- Quarterly cash dividend of $0.66 per share declared, signaling continued shareholder distributions
- November 12, 2026 record date, with payment scheduled for December 17, 2026
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $1.415B, up 6%, with core constant-currency growth of 7% driven by sleep devices and masks
- GAAP diluted EPS $2.92, up 23%; non-GAAP EPS $2.91, up 14%, supported by stronger gross margin
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 announces ResMed’s operating results for the quarter ended September 30, 2026
- Investors should review the accompanying release for revenue, earnings, margins, guidance and business drivers
Item 8.01: Other Events
- $450M accelerated share repurchase announced, signaling capital return following MatrixCare business sale
- $450M payment to Citibank scheduled September 3, 2026, funded by MatrixCare proceeds and cash on hand
AI summaries of RMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RMD
Don't miss the next RMD filing
- Alerts as it files. A push when RMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RMD, by share count.
- Ask anything. An AI agent that reads every RMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DelOrefice Christopher | A | Nov 19, 2026 | 554 | - |
| Tan Desney | A | Nov 19, 2026 | 1,109 | - |
| Burt Carol | A | Nov 19, 2026 | 1,109 | - |
| Leong Justin | A | Nov 19, 2026 | 10,314 | - |
| Drexler Karen | A | Nov 19, 2026 | 1,109 | - |
| Gill Harjit | A | Nov 19, 2026 | 1,109 | - |
| FARRELL PETER C | A | Nov 19, 2026 | 554 | - |
| De Witte Jan | A | Nov 19, 2026 | 1,109 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $5.1B | $5.7B |
| Gross Profit | - | $3.1B | $3.5B |
| Operating Income | - | $1.7B | $1.9B |
| Net Income | - | $1.4B | $1.5B |
| Gross Margin | - | 59.4% | 61.1% |
| Op. Margin | - | 32.7% | 33.4% |
| Net Margin | - | 27.2% | 26.9% |
| Balance Sheet | |||
| Total Assets | $6.9B | $8.2B | $9.0B |
| Equity | - | $6.0B | $6.6B |
| ROE | - | 23.5% | 23.1% |
| Per Share | |||
| EPS | - | $9.51 | $10.43 |
| Cash Flow | |||
| Operating CF | - | $1.8B | $1.8B |
| CapEx | $99.5M | $89.9M | $156.3M |
Source: XBRL data in ResMed (RMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 41 | $11.60B |
| Q2 2026 | 40 | $10.65B |
| Q1 2026 | 40 | $12.24B |
| Q4 2025 | 37 | $13.51B |
| Q3 2025 | 40 | $15.33B |
| Q2 2025 | 37 | $14.28B |
| Q1 2025 | 35 | $9.85B |
| Q4 2024 | 30 | $8.61B |
- Citigroup+152.3K (+20%)
- Renaissance Technologies LLC+92.3K (+5698%)
- T. Rowe Price Group+90.8K (+24%)
- AQR Capital Management+33.9K (+4%)
- Citadel Advisors LLC+19.6K (+4%)
- BNY Mellon−468.4K (-11%)
- Invesco Ltd−369.2K (-18%)
- BlackRock−363.0K (-3%)
- Northern Trust−225.8K (-13%)
- State Street Corp−161.5K (-2%)
- Allstate+17.4K
- Blackstone Group+2.5K
- StoneX Group Inc.+1.9K
- FMR LLC (Fidelity)−216.6K
- Marex Group plc−1.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 300 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Oct 30, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
RMD SEC filings: frequently asked questions
Are RMD insiders buying or selling?
In the last 90 days, ResMed (RMD) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $3.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RMD stock?
As of September 30, 2026, the largest ResMed (RMD) holders among the 13F filers tracked by SignalX were BlackRock ($2.6 billion), Vanguard Capital Management LLC ($2.1 billion), Vanguard Portfolio Management LLC ($1.8 billion), State Street Corp ($1.4 billion), BNY Mellon ($824.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RMD's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), ResMed (RMD) reported revenue of $5.7 billion (up 9.9% from FY2025) and net income of $1.5 billion. Diluted EPS was $10.43. The figures come from the XBRL data in the 10-K.
What are the main risks in RMD's latest 10-K?
In the 10-K filed August 13, 2026, ResMed (RMD) flagged: Direct Medicare oversight risk due to acquisitions of VirtuOx and Noctrix, subject to Anti-Kickback Statute, Stark Law, False Claims Acts, and HIPAA compliance. Geopolitical risk from Uyghur Forced Labor Prevention Act (effective June 2022) and Russia-Ukraine conflict potentially disrupting suppliers of raw materials. (AI summary of the Risk Factors section.)
What did RMD report in its latest 8-K?
ResMed (RMD) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Ronald Taylor retired from the Board at the November 18, 2026 annual meeting, reducing director count from 11 to 10.
What are the latest RMD SEC filings?
ResMed (RMD) filed its latest 10-K annual report on August 13, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 20, 2026.
What is RMD's SEC CIK number?
ResMed (RMD)'s SEC Central Index Key (CIK) is 943819. EDGAR lists every RMD filing under that number.
Ask anything about RMD
The research agent reads RMD's filings, financials, insider trades and 13F holders, then answers with sources.